aibioBy aibio.space
Alto has about $338 million pro forma, but two Phase 2 trials missed and burn is rising
Alto reports $243.7 million, plus $94.6 million net from a July offering. Our arithmetic gives 43 to 59 months. But ALTO-100 and ALTO-101 both missed in Phase 2, and quarterly spending is up sharply.
ANRO Mixed view The balance is large and the July offering is sized, but two Phase 2 trials missed their endpoints and spending has more than doubled.
Alto Neuroscience uses a biomarker platform to find the patients its psychiatric drugs are tested on. The latest 10-Q puts its cash and short-term investments at $243.7 million. We think that balance gives the company room. Spending has risen sharply, though, and the company's own cash claim is far shorter than our arithmetic. The burn is the number to watch, not the balance.
What the company does and where it is
The annual report describes a precision medicine platform. The company applies data analytics and machine learning to samples from its own and third-party trials, to find biomarkers that sort patients into groups. It focuses on MDD, BPD and schizophrenia, and the report calls that approach unproven. The company says it has never obtained approval for, or commercialized, a drug. It reported negative topline results in October 2024 for ALTO-100 in MDD.
The 10-Q lists five programs in its research table: ALTO-100, ALTO-300, ALTO-101, ALTO-203 and ALTO-207. It says ALTO-207 was acquired in May 2025 and that a Phase 2b trial of it started in April 2026. The 10-Q also says that in April 2026 the Phase 2 proof-of-concept trial of ALTO-101, in cognitive impairment associated with schizophrenia, did not reach statistical significance on its primary EEG or cognitive endpoints against placebo. The closest result was a theta-ITC effect in 83 patients with p=0.052. The company points to later analyses of subgroups and secondary measures. We treat those as ideas for a new trial, not as evidence of benefit. The 10-Q describes the ALTO-100 failure in MDD the same way, leaning on a subgroup of adjunctive patients. Both misses are in the company's own filing.
Cash and burn
Cash, cash equivalents and short-term investments were $243.7 million at June 30, 2026. That is down from $263.8 million at March 31, 2026, and up from $176.5 million at December 31, 2025.
Operating cash outflow was $9.9 million in the quarter ended September 30, 2025, $11.5 million in the quarter ended December 31, 2025, $27.1 million in the quarter ended March 31, 2026 and $19.8 million in the quarter ended June 30, 2026. These are derived from year-to-date totals. The average over the last four quarters is $17.1 million. The average over the last two is $23.4 million.
Our runway arithmetic is simple. $243.7 million divided by $17.1 million a quarter is 14.3 quarters, or about 43 months. At the two-quarter average of $23.4 million, the same cash lasts less time. This is our arithmetic, not guidance, and counts no new money.
What management says about its cash
The company's claim is much shorter. The latest 10-Q says existing cash, plus the net proceeds of the July 2026 Offering and anticipated proceeds under a Convertible Grant Agreement with Wellcome, will be sufficient to fund operating expenses and capital expenditures for at least the next 12 months. That is a floor, not a forecast. The 10-Q does size the money. The July 2026 offering was 3,776,436 shares at $26.48, with net proceeds of about $94.6 million, closed on July 14 with BofA Securities as representative of the underwriters. The Wellcome agreement is a convertible loan of up to about $11.7 million, which Wellcome can convert into shares at a 20% discount to a 30-day average price. The company also has a term loan with about $17.1 million of principal and exit fee still to pay.
Why the gap? Our 43 months counts only the June balance at the four-quarter rate. Adding the July net proceeds gives about $338.3 million (our sum). At the four-quarter average of $17.1 million that is about 59 months, and at the two-quarter average of $23.4 million it is about 43 months. The 12 months in the filing is the going concern test, and it does not say which burn rate management uses.
The filing also says the company must keep at least five months of cash runway at all times, measured on trailing three-month cash use. That covenant is waived while market capitalization is above $700.0 million. The 10-Q cover shows 39,242,104 shares outstanding on August 7, 2026. At the July offering price of $26.48 that is about $1.04 billion (our arithmetic), above the $700.0 million line, so the waiver applied at that price. If the stock fell far below $17.84, the line would bind again.
The earlier financing item we have is a shelf. In February 2025 the company filed a $300,000,000 shelf registration with a $75,000,000 at-the-market program, under a sales agreement with Leerink Partners signed on February 3, 2025. The filings we have do not say how much of that program was sold, so we cannot tie it to the March 2026 rise.
Where the money goes
Research and development cost $22.1 million in the quarter ended June 30, 2026, against $13.1 million a year earlier. General and administrative cost was $7.0 million, against $5.6 million. The 10-Q puts the largest part of the research increase on ALTO-207, with about $6.4 million more spent on clinical and manufacturing work to launch the Phase 2b trial. For the six months, research spending was $42.4 million, against $23.1 million.
Quarterly research spending rose from $10.5 million in the quarter ended September 30, 2025, to $22.1 million in the quarter ended June 30, 2026. The net loss went from $14.2 million to $27.6 million over the same period. The passages we have give no budget for the trials now running, so we cannot say where spending levels off.
The bull case
The bull case starts with the balance. $243.7 million is large next to the latest quarterly outflow of $19.8 million. The filing says one platform serves all its programs. The company's own claim also counts net proceeds of the July offering and anticipated Wellcome grant money, so it has more room than the cash-only figure. The filing says a setback in one program can hurt the others. The filing does not say success helps them.
The bear case
Operating outflow averaged $23.4 million over the last two quarters, against $17.1 million over four. Research spending has more than doubled since the September 2025 quarter. The company's own runway claim is at least 12 months and depends on money we cannot size. ALTO-100 reported negative topline results in MDD in October 2024, and ALTO-101 missed its primary endpoints in April 2026. The platform's central claim is that biomarkers pick the patients who respond. Two Phase 2 trials have not delivered that, and the annual report itself calls the approach unproven. The next readouts are Phase 2 trials: ALTO-300 in the first half of 2027, ALTO-100 in bipolar depression in mid-2027 and ALTO-207 in the second half of 2027. The company has never had a drug approved.
Our view
Our view is that the bear case is stronger, though not by a wide margin. We think the balance is real and buys time. The bigger problem is the spending curve. Quarterly outflows are higher than a year ago, research cost has more than doubled, and the science has not yet shown that the platform picks winners. Two Phase 2 trials missed, and the next readouts are also Phase 2.
We would treat 12 months as the going concern floor and 43 to 59 months as our range. Neither is a plan. This is opinion, not investment advice.
What to watch, and what would change our mind
Quarterly operating outflow. If it stays near the two-quarter average, the runway shortens from our 43 months. The next 10-Q should show the balance after the July offering, so we can test our pro forma figure. Research spending, and whether it levels off near the $22.1 million of the latest quarter. What would change our mind: a positive, statistically significant Phase 2b result from ALTO-100 in bipolar depression, ALTO-300 or ALTO-207, or a quarter of outflow back near the four-quarter average of $17.1 million.